CAD-1005
Heparin-Induced Thrombocytopenia (HIT)
Phase 3-readyActive
Key Facts
Indication
Heparin-Induced Thrombocytopenia (HIT)
Phase
Phase 3-ready
Status
Active
Company
About Cadrenal Therapeutics
Cadrenal Therapeutics is a clinical-stage biotech focused on addressing critical gaps in anticoagulation therapy across acute and chronic settings. Its strategy leverages a differentiated pipeline of three assets targeting high-unmet-need, often orphan, cardiovascular and thrombotic disorders. Key achievements include advancing its lead asset, CAD-1005 for HIT, to Phase 3 readiness with Orphan Drug and Fast Track designations, and positioning tecarfarin for Phase 3 trials in end-stage kidney disease and LVAD patients. The company aims to deliver targeted therapies where current standards are inadequate or carry significant risk.
View full company profile